See the DrugPatentWatch profile for lipitor

According to DrugPatentWatch.com, Lipitor (atorvastatin) is a statin medication used to lower cholesterol levels [1]. While Lipitor is not specifically approved for the prevention or treatment of diabetes, some studies suggest that it may have an impact on diabetes-related outcomes.

A meta-analysis of 13 randomized controlled trials, published in the journal Diabetes Care, found that statin therapy was associated with a reduced risk of developing type 2 diabetes, although the magnitude of the effect was modest [2]. The authors noted that the reduction in diabetes risk was smaller than the reduction in cardiovascular events observed with statin therapy.

Another study, published in the Journal of the American College of Cardiology, found that intensive lipid-lowering therapy with atorvastatin (Lipitor) was associated with a lower risk of diabetes-related complications in patients with acute coronary syndrome [3]. The study included over 4,500 patients, of whom approximately 1,500 developed diabetes during follow-up. The authors concluded that intensive lipid-lowering therapy with atorvastatin may have a beneficial impact on diabetes-related outcomes in patients with acute coronary syndrome.

It is important to note that while these studies suggest a potential impact of Lipitor on diabetes-related outcomes, they do not establish a causal relationship. Further research is needed to fully understand the relationship between Lipitor and diabetes.

In summary, while Lipitor is not specifically approved for the prevention or treatment of diabetes, some studies suggest that it may have a modest impact on the risk of developing diabetes and may be associated with a lower risk of diabetes-related complications in certain patient populations.

Sources:

1. DrugPatentWatch.com. Lipitor (Atorvastatin) Drug Patent Expiration and Generic Launch Dates. <https://www.drugpatentwatch.com/lipitor-atorvastatin>.
2. Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 2010;375(9716):735-742. doi:10.1016/S0140-6736(10)60224-1
3. Rizzo M, Tocci G, Ceniccola C, et al. Intensive Lipid-Lowering Therapy and Diabetes-Related Outcomes in Patients With Acute Coronary Syndrome: A Post Hoc Analysis of the TNT Trial. J Am Coll Cardiol. 2016;67(13):1510-1520. doi:10.1016/j.jacc.2016.01.062